Share on StockTwits

Fresh from its failed (or at least paused) attempt to acquire rival AstraZeneca, Pfizer has made a big bet on one of the hottest new technologies in cancer: genetically engineered white blood cells that hunt down tumors and destroy them. Pfizer announced this morning that it will pay Cellectis, a French biotechnology company, an $80 million upfront payment for the company’s T-cell technology, in addition to purchasing about $30 million in stock. Pfizer will also foot the bill for some ongoing research and development, and will pay up to $185 million in milestone payments for each of 15 programs that it will be developing to use the tumor-killing cells, known as chimeric antigen receptor T-cells.

“Pfizer Antes Up $110 Million To Buy In To Cancer Cell Therapy Race” is categorized as “business”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.